PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)

被引：0
|
作者：
Abraham, Jean E.
Pinilla, Karen
Grybowicz, Louise
Dayimu, Alimu
Demiris, Nikolaos
Harvey, Caron
Drewett, Lynsey M.
Lucey, Rebecca
Fulton, Alexander
Roberts, Anne N.
Worley, Joanna R.
Chhabra, Anita
Qian, Wendi
Hardy, Richard M.
Chan, Stephen
Hickish, Tamas
Tripathi, Devashish
Venkitaraman, Ramachandran
Persic, Mojca
Aslam, Shahzeena
Glassman, Daniel
Raj, Sanjay
Borley, Annabel
Braybrooke, Jeremy P.
Sutherland, Stephanie
Staples, Emma
Scott, Lucy C.
Davies, Mark
Palmer, Cheryl A.
Moody, Margaret
Churn, Mark J.
Newby, Jacqueline C.
Mukesh, B. Mukesh
Chakrabarti, Amitabha
Roylance, Rebecca R.
Schouten, Philip C.
Levitt, Nicola
McAdam, Karen
Armstrong, Anne C.
Copson, Ellen R.
McMurtry, Emma
Tischkowitz, Marc
Provenzano, Elena
Earl, Helena
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT012
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PARTNER: randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Abraham, Jean E.
    Pinilla, Karren
    Vallier, Anne-Laure
    Grybowicz, Louise
    Qian, Wendi
    Thomas, Stanly
    Weiss, Melanie
    Harvey, Caron
    Kateb, Angels
    Machin, Andrea
    Demiris, Nikolaos
    Wulff, Jerome
    McAdam, Karen
    Hughes-Davies, Luke
    Roberts, Anne
    Roylance, Rebecca
    Copson, Ellen
    Armstrong, Anne
    Levitt, Nicky
    Provenzano, Elena
    Tischkowitz, Marc
    McMurtry, Emma
    Earl, Helena
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 585 - 586
  • [42] PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Drewett, Lynsey M.
    Pinilla, Karen A.
    Grybowicz, Louise
    Wulff, Jerome
    Dayimu, Alimu
    Demiris, Nikolaos
    Martin, Jessica
    De Pontes, Camila Maida
    Johnson, Nicola
    Harvey, Caron
    Demir, Erdem
    Green, Kimberley St John
    Jones, James
    Young, Gemma
    Vallier, Anne-Laure
    Qian, Wendi
    Machin, Andrea
    McAdam, Karen
    Roylance, Rebecca
    Copson, Ellen R.
    Armstrong, Anne
    Levitt, Nicola
    Provenzano, Elena
    Tischkowitz, Marc
    McMurtry, Emma
    Earl, Helena
    Abraham, Jean E.
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [43] PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Abraham, J.
    Vallier, A-L
    Qian, W.
    Machin, A.
    Grybowicz, L.
    Thomas, S.
    Weiss, M.
    Harvey, C.
    McAdam, K.
    Hughes-Davies, L.
    Roberts, A.
    Roylance, R.
    Copson, E.
    Pinilla, K.
    Armstrong, A.
    Provenzano, E.
    Tischkowitz, M.
    McMurty, E.
    Earl, H.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [44] PARTNER: Randomised, phase 2/3 trial evaluating safety & efficacy of adding olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Abraham, Jean
    Vallier, Anne-Laure
    Qian, Wendi
    Machin, Andrea
    Grybowicz, Louise
    Thomas, Stanly
    Weiss, Melanie
    Harvey, Caron
    McAdam, Karen
    Hughes-Davies, Luke
    Roberts, Anne
    Roylance, Rebecca
    Copson, Ellen
    Pinilla, Karen
    Armstrong, Anne
    Provenzano, Elena
    Tischkowitz, Marc
    McMurtry, Emma
    Earl, Helena
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 45 - 45
  • [45] Subtyping of triple-negative breast cancer (TNBC): A cohort study
    Thomssen, Christoph
    Hartung, Caroline
    Porsch, Martin
    Stuckrath, Kathrin
    Buchmann, Jorg
    Kantelhardt, Eva J.
    Vetter, Martina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Receptor Concordance in Triple Negative Breast Cancer (TNBC) Recurrences.
    Killian, M. E.
    De Los Santos, J. F.
    Forero-Torres, A.
    Krontiras, H.
    [J]. CANCER RESEARCH, 2011, 71
  • [47] HuR regulates aerobic glycolysis in triple negative breast cancer (TNBC)
    Dev, Arundhathi J. R.
    Gogia, Ajay
    Mathur, Sandeep R.
    Deo, S. V. S.
    Prasad, Chandra Prakash
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [48] A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC)
    Damodaran, Senthil
    Liu, Diane
    Schwartz, Jill
    Valero, Vicente
    Ramirez, David
    Saleem, Sadia
    Ueno, Naoto T.
    Ibrahim, Nuhad K.
    Karuturi, Meghan S.
    Murthy, Rashmi K.
    Moulder, Stacy
    Litton, Jennifer K.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [49] Neoadjuvant phase II trial with carboplatin and eribulin in triple negative breast cancer patients
    Giordano, S. B.
    Jeruss, J. S.
    Bethke, K. P.
    Hansen, N. M.
    Khan, S.
    Von Roenn, J.
    Rosen, S.
    Gradishar, W. L.
    Siziopikou, K. P.
    Meservey, C.
    Kaklamani, V.
    [J]. CANCER RESEARCH, 2013, 73
  • [50] Neoadjuvant carboplatin and docetaxel in locally advanced triple negative breast cancer: A Hispanic trial
    Gomez, Saul Campos
    Gomez, Karen Angelica Campos
    Garces, Marciela Garcia
    Morelos, Gladys
    Alvarez, Jesus Hernandez
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345